

1 **Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated**
2 **arthritis and preventing relapse during ICI rechallenge: the TAPIR study**

3 Pierre-Florent Petit^{1‡}, Douglas Daoudlarian^{2‡}, Sofiya Latifyan³, Hasna Bouchaab³,
4 Nuria Mederos³, Jacqueline Doms², Karim Abdelhamid³, Nabila Ferahta³, Lucrezia
5 Mencarelli², Victor Joo², Robin Bartolini², Athina Stravodimou³, Keyvan Shabafrouz³,
6 Giuseppe Pantaleo², Solange Peters³, Michel Obeid^{2*}

7

8 ¹Medical oncology service, CHU Helora, Rue Ferrer 159, 7100 La Louvière, Belgium

9 ²Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
10 Medicine, Immunology and Allergy Service, Rue du Bugnon 46, CH-1011 Lausanne,
11 Switzerland

12 ³Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
13 Oncology, Medical Oncology Service, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland

14 ‡contributed equally to this work

15

16 ***Corresponding author:**

17 Pr Michel Obeid, MD-PhD

18 Lausanne Center for Immuno-Oncology Toxicities LCIT

19 Immunology and Allergy Division, Rue du Bugnon 17, 1011 Lausanne, Switzerland

20 Centre Hospitalier Universitaire Vaudois (CHUV)

21 **Email:** michel.obeid@chuv.ch

22

23 **KEY WORDS:** immune checkpoint inhibitors, irAEs, arthritis, secondary prophylaxis,
24 tocilizumab

25

26

27

28

29 **Abstract**

30 **Background.** Immune checkpoint inhibitor (ICI)-associated arthritis (ICI-AR) significantly
31 affects quality of life and often requires discontinuation of ICI therapy and initiation of
32 immunosuppressive treatment. The aim of this retrospective study was to evaluate the dual
33 efficacy of tocilizumab (TCZ), an anti-IL-6R agent, in the treatment of ICI-AR and the
34 prevention of relapses after ICI rechallenge.

35 **Methods.** This retrospective single-center study was conducted at our institution from 2020
36 to the end of 2023. We identified 26 patients who developed ICI-AR. The primary objectives
37 were to evaluate the therapeutic efficacy of TCZ in the treatment of ICI-AR in 26 patients and
38 to evaluate the potential of TCZ as secondary prophylaxis during ICI rechallenge in 11 of
39 them. For the treatment of ICI-AR, patients received prednisone (CS) at a low dose of 0.3
40 mg/kg tapered at 0.05 mg/kg weekly for six weeks until discontinuation. TCZ was
41 administered at a dose of 8 mg/kg every two weeks. In the subgroup receiving secondary
42 prophylaxis (rechallenge n=11, in 10 patients), TCZ was reintroduced at the same dosage of 8
43 mg/kg bi-weekly concurrently with ICI rechallenge, and without the addition of CS. A control
44 group of patients (rechallenge n=5, in 3 patients) was rechallenged without TCZ. Secondary
45 endpoints included post rechallenge evaluation of ICI duration, reintroduction of CS > 0.1
46 mg/kg/day, ICI-RA flares, and disease control rate (DCR). An additional explanatory endpoint
47 was the identification of biomarkers predictive of response to TCZ.

48 **Results.** The median age of the patients was 70 years. The median follow-up from ICI
49 initiation was 864 days. ICI regimens included anti-PD-(L)1 monotherapy in 17 patients
50 (63%), anti-PD-1 combined with anti-CTLA4 therapy in 8 patients (31%), and anti-PD-1
51 combined with anti-LAG3 therapy in 1 patient (4%). Among the 20 patients treated with TCZ
52 for ICI-AR, all (100%) achieved an ACR70 response rate, defined as greater than 70%

53 improvement, at 10 weeks. Additionally, 81% of these patients achieved steroid-free
54 remission after 24 weeks on TCZ.

55 The median follow-up period was 552 days in rechallenged patients. The ICI rechallenge
56 regimens (n=16) included anti-PD-(L)1 monotherapy in thirteen cases (81%) and combination
57 therapy in three cases (19%). The results demonstrated a reduction in ICI-AR relapses upon
58 ICI rechallenge in patients receiving TCZ prophylaxis as compared to patients who did not
59 receive prophylaxis (17% vs 40%). In addition, the requirement for CS at doses exceeding 0.1
60 mg/kg/day was completely abolished with prophylaxis (0% vs 20%), and the mean duration
61 of ICI treatment was notably extended from 113 days to 206 days. The 12-month post-
62 rechallenge outcomes showed a disease control rate (DCR) of 77%. Importantly, during TCZ
63 prophylaxis, CXCL9 levels remained elevated, showing no decline from their levels at the
64 onset of ICI-AR. Additionally, elevations of IL-6 and CXCL10 levels were exclusively
65 observed in patients who developed new irAEs during the period of TCZ prophylaxis.

66 **Conclusion.** In addition to its efficacy in treating ICI-AR, TCZ demonstrated efficacy as a
67 secondary prophylactic agent, preventing the recurrence of ICI-AR symptoms and
68 lengthening ICI treatment duration after ICI rechallenge. The use of TCZ as a secondary
69 prophylaxis may represent a promising strategy to extend patient exposure to ICI treatments
70 and maximize therapeutic benefit.

71

72

73 **Highlights**

- 74 1- TCZ achieved a 100% ACR70 response rate at 24 weeks, demonstrating its efficacy in
75 the treatment of ICI-RA.
- 76 2- A significant 81% of patients achieved steroid-free status after 24 weeks on TCZ,
77 underscoring its utility in accelerating CS tapering.
- 78 3- TCZ serves as a successful secondary prophylaxis in patients rechallenged with ICI,
79 preventing significant arthritis flares and the need for additional CS use.
- 80 4- TCZ prophylaxis reduces the median time to ICI rechallenge by 47.5 days and extends
81 the duration of uninterrupted ICI therapy by 93 days.
- 82 5- CXCL9 levels were not reduced during TCZ prophylaxis, suggesting that there was no
83 negative impact on cytokines associated with oncologic response. In addition, early
84 increases in IL-6 and CXCL10 levels may signal the onset of new irAEs during
85 prophylaxis.

86

87 **Introduction**

88 Immune checkpoint inhibitor-associated arthritis (ICI-AR) can be persistent and significantly
89 impacts patients' quality of life, necessitating discontinuation of ICI therapy and long-term
90 use of immunosuppressants^{1, 2}. Although clinical trials report arthralgia incidence rates
91 ranging from 5 to 11%, expert opinion suggests that these immune-related adverse events
92 (irAEs) may be underreported^{3, 4}. The most common rheumatic (rh) irAEs include
93 inflammatory polyarthritis and polymyalgia rheumatica (PMR)-like syndromes⁵⁻⁷. In contrast
94 to the classical findings observed in patients with rheumatoid arthritis, patients with ICI-AR
95 are rarely positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA)⁴.

96 The pathogenesis of ICI-RA remains incompletely understood. The composition of immune
97 cells in the synovial fluid differs significantly from that observed in patients with rheumatoid
98 or psoriatic arthritis⁸. Recent studies have identified a significant clonal expansion of
99 activated effector CD8⁺ T cell populations, including CD38^{hi}CD127⁻ and CXCR3^{hi} subsets in
100 synovial fluid, and CX3CR1^{hi} CD8⁺ T cells in blood^{9, 10}. In contrast to IL-6, levels of IFN- γ ,
101 TNF- α , and the Th17 signature are reduced in both peripheral blood and synovial fluid
102 following immunosuppressive treatment in ICI-RA patients⁹. However, the precise extent of
103 inflammatory cytokine fluctuation relative to baseline levels in cancer patients prior to ICI
104 treatment remains unknown, representing a substantial gap in our data continuum. The lack of
105 comprehensive data on the fluctuations of cytokines limits the identification of reliable
106 biomarkers for the monitoring of ICI-RA progression and the prediction of treatment
107 outcomes. Consequently, the establishment of comprehensive baseline and longitudinal
108 cytokines profiling is of paramount importance for the advancement of our understanding and
109 the improvement of ICI-RA management

110 Tocilizumab (TCZ), an interleukin-6 receptor (IL-6R) inhibitor, is approved for the treatment
111 of many rheumatic diseases, including rheumatoid arthritis, systemic juvenile idiopathic
112 arthritis and giant cell arteritis. It has recently emerged as a promising therapeutic alternative
113 for the treatment of irAEs due to its specificity and potential to attenuate systemic
114 inflammation without suppressing T-cell activity or compromising the anti-tumor immune
115 response¹¹⁻¹³. Recent studies have demonstrated the efficacy of TCZ in the treatment of
116 rheumatoid irAEs while preserving the anti-tumor immune response¹⁴⁻¹⁷.

117 Furthermore, the incidence of identical irAEs flares following ICI rechallenge exhibits
118 considerable variability, with reported recurrence rates ranging from 18% to 42% across
119 various studies¹⁸⁻²². These relapses can be of increased severity, particularly if the initial irAEs
120 were of high grade. Notwithstanding the difficulties inherent to ICI therapy resumption

121 following severe irAEs, it remains a viable option for a subset of patients who have
122 previously demonstrated a favorable response to ICI retreatment. Our team has previously
123 proposed the use of selective immunosuppression (SI), such as TCZ for arthritis and
124 vedolizumab for colitis, as a secondary prevention when restarting ICI treatment²². Previous
125 reports on prophylaxis for ICI-associated colitis have indicated that the recurrence rate of
126 severe ICI-associated colitis following ICI rechallenge was lower in patients receiving
127 prophylaxis with vedolizumab or infliximab compared to those not receiving prophylaxis²³,
128 ²⁴. These preventive approaches aim to achieve a balance between efficacy and safety, taking
129 advantage of the favorable safety profile of SI to facilitate ICI retreatment. Nevertheless, the
130 efficacy of TCZ as a secondary prophylaxis in the reintroduction of ICI therapy after IRI-RA
131 has not been subjected to a comprehensive evaluation.

132 The primary objective of this study is to investigate the dual functionality of TCZ as a
133 treatment of ICI-AR and as a prophylactic agent during subsequent ICI rechallenge. A
134 retrospective analysis was conducted on a cohort of 26 cancer patients diagnosed with ICI-
135 AR. This analysis included sequential deep inflammatory profiling of 57 cytokines at four
136 critical time points: baseline prior to the initiation of ICI therapy, at the time of ICI-AR
137 diagnosis, prior to ICI rechallenge, and during ICI rechallenge with TCZ prophylaxis. The
138 data from these patients were compared with those from a larger cohort of cancer patients
139 prior to ICI treatment (n=164) to ascertain inflammatory profiles associated with the onset of
140 ICI-AR and to identify biomarkers predictive of the efficacy of TCZ, both as a treatment and
141 as a prophylactic measure.

142

143

144 **RESULTS**

145 **Clinical demographic and rh-irAE characteristics.** A total of 31 patients treated at the
146 Lausanne University Hospital between 2020 and the end of 2023 were identified with rh-
147 irAEs following ICI treatment. Of these, 26 patients with ICI-related arthritis (ICI-RA) were
148 included in the final analysis, as described in the study flowchart (**Supplementary Figure 1**).
149 Patient characteristics are summarized in Table 1. The mean age of the patients was 70 years,
150 with a male predominance (n=15/26, 58%). The most common types of cancer were
151 melanoma and lung cancer, with 11 out of 26 patients (42%) for each tumor type. The
152 majority of the patients were treated with anti-PD-1 monotherapy (n=16/26, 62%) or the
153 combination of nivolumab plus ipilimumab (n=8/26, 31%).

154 The median time from the onset of ICI treatment to the onset of rh-irAEs was 171 days (95%
155 CI: 53-326). The median follow-up period following the initial ICI administration was 864
156 days (95% CI: 576-1152). The median duration of rh-irAEs was 360 days (95% CI:271-546).
157 The most common clinical presentation was polyarticular arthritis (n=14, 54%), while PMR-
158 like arthralgia (n=7, 27%) and oligoarticular arthritis (n=5, 19%) were less prevalent. All
159 patients tested negative for rheumatoid factor (RF) and anti-citrullinated protein antibodies
160 (ACPA) (n=0/26, 0%). A history of pre-existing non-active inflammatory rheumatic disease
161 was documented in only 20% (n=5/26) of patients, and none were receiving
162 immunosuppressive drugs (IS) at the time of ICI initiation. A proportion of patients (n=17/26,
163 53%) developed other concomitant immune-related adverse events (irAEs) (**Table 1**).

164

165 **Tocilizumab is an effective treatment for ICI-AR and allows CS tapering.** In the patient
166 group (n=20/26, 77%) treated with biweekly TCZ at a dosage of 8 mg/kg, in combination
167 with a low dose of prednisone CS at 0.3 mg/kg/day, 100% of the patients achieved an ACR70

168 arthritis score²⁵⁻²⁷ (indicating at least 70% improvement from baseline) by weeks 10-12.
169 Notably, this rapid improvement was also observed in two patients who received TCZ without
170 CS (n=2/20, 10%). TCZ consistently enabled patients to achieve ACR70 score at both 10-12
171 and 24-weeks following the onset of ICI-AR, as shown in **Table 2**. 24 weeks (24W) after the
172 introduction of TCZ, 81% of patients (n=13/16) achieved a steroid-free status. The mean CS
173 dose was 23 mg and the average time to reduce CS to less than 10 mg after starting TCZ was
174 30.7 days. The median duration of TCZ treatment was 235 days (95% CI: 55-450). In
175 contrast, those treated with CS alone (n=6) had less favorable outcomes. At 24 weeks, only
176 25% of these patients achieved steroid-free status, compared to 81% in the TCZ-treated
177 group. In addition, this group required a higher mean CS dose of 37.5 mg compared to 23 mg
178 in the TCZ group, and they required longer time - an average of 40.25 days versus 30.7 days -
179 to taper their CS dose to below 10 mg (**Table 2**). This comparison underscores TCZ rapid
180 efficacy in treating ICI-AR and highlights the associated benefits in terms of reducing both
181 CS dosage and treatment duration.

182

183 **Tocilizumab prophylaxis facilitates ICI rechallenge and reduces ICI-AR relapse.** After
184 completing CS tapering and the resolution of ICI-AR, 13 patients underwent ICI rechallenge,
185 including three undergoing rechallenge twice, for a total of 16 rechallenge episodes (RCLs).
186 TCZ was employed as secondary prophylaxis (TP) in 11 RCLs, while the remaining 5 RCLs
187 proceeded without TCZ prophylaxis (WP). The same ICI was reintroduced in 91% of RCLs
188 (n=10/11) in the TP subgroup, compared to 60% (n=3/5) in the WP subgroup. The median
189 interval between end of initial ICI and ICI rechallenge was 70 days (95% CI:56-84) in the WP
190 group vs 22.5 days (95% CI:20-295) in the TP group, with a median follow-up duration post-
191 rechallenge of 498 days (95% CI:341-1040) in the TP group vs 566 days (95% CI:129-757) in

192 the WP group. At the time of ICI rechallenge, oncological disease was progressing in 6
193 cases—40% in the WP subgroup and 36% in the TP subgroup.

194 In the TP subgroup (n=11), the incidence of ICI-AR relapses decreased to 18%, compared to
195 40% in the WP group. Moreover, the requirement for reintroduction of CS at doses exceeding
196 0.1 mg/kg/day dropped to 0% in the TP group versus 20% in the WP group. The mean
197 duration of ICI treatment in the TP group notably extended to 206 days (95% CI:78-333)
198 compared to 113 days (95% CI:16-210) in the WP group. At the last follow-up, ongoing ICI
199 treatment was observed in 36% (n=4/11) of the TP group, compared to none in the WP group.

200 In the TP group, the percentage of ICI interruption post-rechallenge due to irAEs was 27%, as
201 opposed to 40% in the WP group. These results are summarized in Table 3.

202 These results indicate that TCZ prophylaxis can reduce the recurrence of ICI-AR and prevent
203 the escalation of CS use. In addition, TCZ was associated with a shorter interval between
204 initial ICI cessation and ICI rechallenge, and with lower incidence of new irAE development.
205 Consequently, TCZ prophylaxis prolonged the duration of ICI treatment.

206

207 **Oncological outcome and treatment response.** Table 4 describes the oncologic outcome
208 after ICI-RA in patients with definitive ICI discontinuation (n=13). In these patients, the last
209 ICI injection was administered on average 19.6 days after the start of ICI-RA. We observed
210 few cases of progressive disease in these patients (n=1, 8%), while some presented oligo-
211 metastatic progression that was treated with local therapy (at 6 months, n=3; at 12 months,
212 n=2). Disease control rates (DCR) were 78% at 6 months and 71% at 12 months in the
213 absence of systemic treatment. We then evaluated the oncological response in rechallenged
214 patients. These patients had worse outcomes after ICI-RA initiation, as 4 patients were
215 rechallenged due to disease progression. Nevertheless, the DCR after rechallenge was 82% at

216 6 months and 70% at 12 months. The swimmer plot in Figure 1 illustrates ICI treatment and
217 oncological outcomes of patients over time.

218 Due to the retrospective design of the study, the 2 cohorts (no rechallenge and rechallenge)
219 were biased by oncologist decisions. Patients who develop ICI-RA are commonly associated
220 with a good prognosis. In our cohort, ICI rechallenge was preferentially performed in patients
221 with worse oncologic prognosis, with 4 patients out of 13 patients presenting disease
222 progression at the time of rechallenge initiation (**supplementary Table 1**).

223 ICI rechallenge was performed with TCZ prophylaxis in 10 of the 13 patients. Oncologic
224 responses were likely achieved due prolonged exposure to ICI treatment. These results
225 underscore the potential of TCZ prophylaxis not only for the management and prevention of
226 ICI-RA, but also for the prolongation of ICI treatment leading to durable disease control.

227

228 **A comprehensive profile of cytokine and biological variation.** To investigate the
229 inflammatory profile associated with ICI-AR, we evaluated a large spectrum of classical and
230 inflammatory biomarkers prior to the introduction of immunosuppressive therapy. Our
231 analysis focused on the serum levels of 57 cytokines, chemokines, and growth factors. Among
232 these, only four—CXCL9, CXCL10, IL-6, and the anti-inflammatory cytokine IL-1RA—
233 demonstrated elevated levels at the onset of ICI-AR compared to the baseline levels in cancer
234 patients prior to starting ICI therapy (**Figure 2 and supplementary table 2**). At the time of
235 rechallenge, after the cessation of CS and TCZ treatment, the levels of CXCL9, CXCL10, and
236 IL-1RA continued to be elevated while levels of IL-6 did not. This pattern suggests a
237 sustained inflammatory response independent of IL-6.

238 During ICI rechallenge with TCZ prophylaxis, the levels of these cytokines were relatively
239 stable, consistent with their levels at ICI-AR onset and at RCL baseline. Notably, the levels of

240 CXCL10 and IL-6 increased upon emergence of new irAEs following ICI rechallenge under
241 TCZ prophylaxis, indicating their potential utility in predicting the development of new irAEs
242 despite ongoing TCZ prophylaxis (**Figure 2 and supplementary table 2**).

243

244 **Figures legend**

245 **Table 1. Clinical, demographic, biological and rh-irAEs characteristics of the ICI-AR**
246 **cohort.** The principal clinical, biological, demographic, and rh-irAEs characteristics for the
247 ICI-AR cohort (n=26) are detailed in this table.

248

249 **Table 2. Immunosuppressive treatments and patient responses in the ICI-AR cohort.** The
250 different types of immunosuppressive treatment, and symptoms outcomes under treatment in
251 the ICI-AR cohort (n=26) are detailed in this table. 6 patients were treated with CS alone, 18
252 patients were treated with a combination of TCZ 8 mg/kg Q2w + low dose CS at 0.3
253 mg/kg/day and 2 patients were treated with TCZ 8mg/kg Q2W alone without CS. The
254 ACR50/70 at 10-12w and 24w, the steroid-free status at 24w are detailed. The mean dose of
255 CS and the mean time for <10mg CS in each treatment group are detailed. CS,
256 corticosteroids; TCZ tocilizumab.

257

258 **Table 3. Efficacy of secondary prophylaxis with TCZ in rechallenged patients.** The main
259 clinical characteristics and treatment response of the two groups are described, the TCZ
260 secondary prophylaxis (TP) (Rechallenge n=11, in 10 patients) compared to the rechallenged
261 group without TCZ prophylaxis (WP) (Rechallenge n=5, in 3 patients). The median interval
262 between end of initial ICI and rechallenge, the recurrence of rh-irAEs \geq G2, the need for
263 CS>0.1mg/kg/day, the mean duration of ICI treatment and the reason for ICI discontinuation

264 are detailed. PD; progressive disease, G1 and G2; grade 1 and 2, CRS; cytokine release
265 syndrome, CI confidence interval.

266

267 **Figure 1. Swimmer plot showing duration of oncological response in relationship to**
268 **duration of ICI treatment and time of ICI rechallenge in the non-rechallenged (n=13)**
269 **and rechallenged (n=13) groups.** Individual swimmer plots for each patient (n=26). CR,
270 complete response, PR, partial response, PD progressive disease, Oligo-PD, oligo-progressive
271 disease. Arrows indicate in progress ICI rechallenge treatment.

272 **Figure 2. Comprehensive cytokine and biological profiles at different timepoints**
273 **compared to cancer patient baseline. (a-f),** Evaluation of serum biomarkers in ICI-AR
274 patients at four time points: the time of ICI-RA onset (n=19), ICI rechallenge baseline (n=7),
275 during ICI rechallenge with TCZ prophylaxis (n=6) and at the time of new irAEs during ICI
276 rechallenge under TCZ prophylaxis (n=5) compared to the pre-ICI serum levels in cancer
277 patients before ICI treatment (n=164) used as the reference group. (a-d) serum levels of
278 chemokines, growth factors and cytokines during the four time points. Mann-Whitney U test
279 tests were used to analyze the data for statistical significance between groups. Plots represent
280 values with individual data points, bar represent the mean and error bars represent standard
281 deviation. The results showed a significant difference between the groups with a P-value of
282 less than 0.05 (*), less than 0.01 (**), less than 0.001 (***) and less than 0.0001 (****).

283

284 **Supplementary Figure 1:** Study flowchart.

285 **Supplementary Figure 2:** TAPIR retrospective study design, Tocilizumab For Arthritis
286 Prevention with Rh-irAEs.

287 **Supplementary Table 1. Oncological outcomes at 6 and 12 months after initial ICI-RA in**
288 **non-rechallenged (n=13) and rechallenged population (n=13), and after ICI rechallenge**

289 **in the rechallenged group.** The objective response rate (ORR) and disease control rate
290 (DCR) are detailed in the group of patients without ICI rechallenge (n=13) and in the group of
291 patients with ICI rechallenge (n=12, 11 patients on TCZ prophylaxis) 6 and 12 months after
292 the initial ICI-RA. The lower part of the table details disease control rate (DCR) at 6 months
293 and 12 months from rechallenge in the rechallenged group.

294 **Supplementary Table 2. Global cytokine table.** Supplementary Table 2. Global cytokine
295 table. Summary table for 57 cytokine values at four time points: initial rh-irAE onset, before
296 ICI rechallenge, after rechallenge with TCZ prophylaxis, and at new irAE after rechallenge
297 with TCZ prophylaxis: N, mean, min, max, percentiles (25th, 50th, 75th) and SD. The lower
298 limit of detection is included in the table for all cytokines.

299

300 **Material and Methods**

301 **Patient consent, ethical approval and sample collection:** All study participants provided
302 informed consent for the research use of their data through a process called "consentement
303 général," which includes coded data handling to ensure confidentiality. For patients who did
304 not actively object, enrollment was facilitated in accordance with Article 34 of the Swiss
305 Federal Law on Human Research. This study was approved by the cantonal ethics committee,
306 formally known as the Commission Cantonale d'Éthique de la Recherche sur l'Être Humain
307 (CER-VD). Sample collection: All biological samples were collected during routine clinical
308 practice. No specific interventions or modifications of standard care protocols were performed
309 for the purposes of this study.

310

311 **Patient Cohort**

312 **Study design and population.** This retrospective study, titled "Tocilizumab for Arthritis
313 Prevention with Rh-irAEs (TAPIR study)," was conducted at the medical oncology and
314 immunology services of the CHUV between 2020 and the end of 2023. It included a cohort of
315 cancer patients treated with ICIs who developed ICI-AR (n=31). 4 patients declined the
316 consent, 1 patient transferred to another hospital and only 26 were included in the final
317 analysis, as displayed in the flowchart (**Supplemental Figure 1**). **The primary outcomes**
318 were to assess the efficacy of TCZ in treating ICI-AR by evaluating the ACR 20/70 arthritis²⁵⁻
319 ²⁷ score and to determine its potential as a secondary prophylaxis during ICI re-challenge.
320 **Treatment protocol:** TCZ was administered at a dosage of 8 mg/kg biweekly (n=20).
321 Concurrently, patients received low dose of prednisone (CS) at a dosing of 0.3 mg/kg (n=18),
322 which was tapered down by 0.05 mg/kg weekly over a period of 6 weeks, until complete
323 tapering. For those receiving secondary prophylactic treatment (TP) ((Rechallenge n=11, in
324 10 patients), TCZ was readministered at the same dosage of 8 mg/kg every two weeks
325 concurrently with the ICI re-challenge treatment, without the introduction of CS. Another
326 group of patients (Rechallenge n=5, in 3 patients) was rechallenged without TCZ (WP)
327 prophylaxis as mentioned in the study design (**Supplemental Figure 2**). **Clinical follow-up.**
328 Patients under TCZ treatment continued their routine clinical follow-up. The administration of
329 TCZ did not influence oncological treatment decisions. All decisions regarding the ICI re-
330 challenge were made by the referring oncologist. **Secondary outcomes.** ICI duration post
331 rechallenge, reintroduction of CS >0.1mg/kg/day, ICI-RA flares and the objective response
332 rate (ORR) and disease control rate (DCR) were monitored and recorded following the re-
333 challenge with ICI therapy. Explanatory outcomes included biomarker identification that
334 could predict response to TCZ treatment and prophylaxis (**Supplemental Figure 2**).

335

336 **Immune profiling of serum biomarkers.** As previously described²⁸, serum concentrations of
337 cytokines, chemokines, and growth factors were quantified in our study using the Luminex
338 ProcartaPlex immunoassay panel. A comprehensive list of the biomarkers analyzed, their
339 lower limits of detection (LLOD), and the distribution of values within our cohort is provided
340 in Supplementary Table XX. Values recorded below or equal to the LLOD were adjusted to
341 the LLOD to ensure analytical consistency. Our study included a comparative analysis of two
342 different cohorts. In addition to the ICI-associated arthritis (ICI-AR) cohort of 26 patients, we
343 collected baseline serum samples from a large cohort of cancer patients (n=164) prior to ICI
344 treatment to determine pretreatment cytokine levels in a variety of tumor types. Cytokine
345 levels were assessed longitudinally at several critical time points: at the onset of ICI-AR, at
346 the time of ICI rechallenge, and throughout the course of TCZ prophylaxis treatment. This
347 longitudinal approach allowed for a dynamic understanding of how cytokine profiles evolve
348 in response to both disease progression and therapeutic interventions.

349 **Statistical analysis.** All statistical analysis in figures comparing cytokines were performed
350 using GraphPad Prism 10.1.2 (GraphPad Software, Boston, Massachusetts USA).

351

352 **Discussion**

353 The results of this study indicate that the early introduction of TCZ following the onset of
354 ICI-RA, in conjunction with low-dose CS at 0.3 mg/kg, is highly effective for the treatment of
355 ICI-RA, thereby eliminating the need for higher CS dosages. At 10 weeks, a 100% ACR70
356 response rate was achieved, with 81% of patients attaining CS-free remission after 24 weeks.
357 These results are of particular significance as they demonstrate the rapid resolution of arthritis
358 under TCZ, with a remarkable 70% symptom reduction within just 10 weeks of treatment
359 across all participants. These outcomes represent a significant advancement over previous

360 reports, as they establish a clear timeframe—24 weeks—for achieving steroid-free remission,
361 a detail often omitted in earlier studies.

362 This strategy not only rapidly alleviates arthritis symptoms but also significantly improves the
363 possibility of CS tapering. In particular, the duration to obtain CS<10mg was reduced by 24%
364 compared to the CS group and by more than 50% compared to previous studies, which often
365 reported treatment durations exceeding several months^{1, 2, 4, 5}. The mean CS dose (mg) was
366 reduced by 39% compared to the CS group. These results highlight TCZ's potential to
367 streamline and optimize arthritis treatment, reducing both the dose and the duration of CS
368 treatment.

369 Another significant finding of this study was the absence of arthritis flares or the need for CS
370 during rechallenge with ICIs when TCZ was used as a prophylactic agent. This outcome is of
371 particular significance as it addresses an important challenge in the management of patients
372 who have a history of ICI-RA. Typically, the recurrence of arthritis has constituted an obstacle
373 to the continuation of potentially life-saving therapy. Our report underscores the efficacy of
374 TCZ in preventing arthritis flares.

375 CS are frequently employed to address irAEs, but their immunosuppressive impact can
376 diminish the advantages of ICIs²⁹⁻³¹ and introduce complexities in long-term management due
377 to their adverse effects. By reducing the necessity for CS in the treatment of ICI-RA, and by
378 preventing the need for CS after ICI rechallenge, TCZ may help to preserve the integrity of
379 the immune response initiated by ICIs, which is crucial for achieving optimal therapeutic
380 outcomes. Moreover, as previously documented, IL-6 functions as a protumoral cytokine³².
381 Consequently, the use of an anti-IL-6 strategy presents a dual benefit: firstly, it mitigates the
382 adverse effects of CS and secondly, it enhances ICI efficacy by promoting Th1 polarization,
383 thereby optimizing the therapeutic impact of ICIs³³⁻³⁶.

384 It is important to note that the use of TCZ as secondary prophylaxis significantly extended the
385 duration of ICI administration, allowing re-administration for an average of 7.2 months
386 compared to only 3.7 months without prophylaxis. In addition, TCZ prophylaxis significantly
387 shortened the time to ICI rechallenge after initial discontinuation by a factor of 3.11, reducing
388 the interval from 70 days to 22.5 days. At last follow-up, ongoing ICI use was 36% in the
389 TCZ group (TP) versus 0% in the non-prophylaxis group (WP).

390 This is a retrospective study with a small number of patients and it does not allow statistical
391 comparisons between patient groups. Importantly, the decision to rechallenge with ICI was
392 made by oncologists based on evidence of disease progression or a perceived increased risk of
393 progression. Consequently, these two groups of patients are distinct and cannot be directly
394 compared. Nevertheless, we observed a sustained DCR in patients rechallenged with ICI
395 under TCZ prophylaxis, even in patients presenting disease progression at rechallenge
396 initiation. This finding is important because it demonstrates that TCZ prophylaxis may
397 facilitate long-term use of ICIs and achievement of oncologic control, potentially improving
398 overall survival (OS).

399 Our report suggests that TCZ can be effectively incorporated into the arthritis treatment
400 regimen at an early stage and maintained without interruption of ICI therapy as a secondary
401 prevention strategy. These results, among the first of their kind, set a new precedent for the
402 management of ICI-RA and have the potential to significantly change current therapeutic
403 paradigms by providing a more continuous and potentially more effective treatment pathway
404 for patients undergoing ICI therapy.

405 This secondary prevention strategy, which involves the administration of TCZ following the
406 onset of irAEs, contrasts with primary prevention, where TCZ is given preemptively to
407 mitigate the frequency and severity of irAEs³⁷. The determination of the most efficacious
408 approach, whether primary or secondary prevention, requires further research. This necessity

409 is further reinforced by the mounting body of evidence linking the occurrence of irAEs to the
410 efficacy of ICI treatments³⁸⁻⁴¹ and numerous studies that have reported elevated IL-6 levels
411 during irAE episodes^{42, 43}. Furthermore, the intricate network of cytokines may result in
412 unfavorable outcomes when IL-6 signaling is blocked in the initial stages following the
413 initiation of ICI therapy⁴⁴. Accordingly, a more comprehensive investigation into the optimal
414 timing for preventive strategies is of critical importance in this field.

415 In this study, we analyzed the levels of 57 cytokines at the onset of ICI-RA prior to the
416 initiation of immunosuppressive (IS) treatment and compared these levels with baseline
417 measurements in a cohort of cancer patients prior to ICI treatment (n=164). The increase in
418 pro-inflammatory cytokines was limited to IL-6, CXCL9, CXCL10, and IL-RA. Other
419 cytokine, chemokine and growth factor profiles remained stable. Notably, all patients with
420 ICI-RA showed a consistent increase in IL-6 compared to baseline, without the concomitant
421 increase in other inflammatory cytokines typically associated with inflammatory arthritis,
422 such as IL-17⁴⁵, IL-21⁴⁶ and IL-22⁴⁷. IL-6 levels continued to increase during TCZ treatment,
423 as expected, and consistent with previous reports^{11-13, 48, 49}. This distinct cytokine profile
424 highlights the unique inflammatory pathway activated in ICI-RA and underscores the
425 potential for therapeutic targeting of IL-6 in this context. Notably, while previous studies have
426 reported the use of anti-IL-6 receptor therapy for the treatment of ICI-RA^{17, 50}, they have not
427 investigated longitudinal changes in cytokine levels. Our study fills this gap by assessing
428 these variations, providing a deeper understanding of cytokine dynamics over the course of
429 treatment and highlighting the potential importance of these changes in guiding therapeutic
430 decisions. This approach not only validates the role of IL-6, but also suggests the utility of
431 monitoring cytokine profiles as a component of personalized treatment strategies.

432 It is noteworthy that we observed an increase in CXCL9 levels during TCZ prophylaxis,
433 similar to the levels observed at the onset of ICI-RA. This increase is clinically significant, as

434 previously reported, as elevated serum CXCL9 during ICI-RA correlates with favorable
435 oncological outcomes⁵¹. Furthermore, intratumoral increases in CXCL9, a chemokine
436 essential for immune cell recruitment, have been associated with enhanced therapeutic
437 responses in patients undergoing ICIs⁵². During TCZ prophylaxis, the stability of CXCL9
438 levels suggests that the inflammatory and immune-stimulatory milieu necessary for ICI
439 efficacy is maintained. The non-reduction of CXCL9 levels suggest that, despite the
440 immunosuppressive action of TCZ (which is primarily aimed at IL-6 blockade), the immune
441 system's ability to recruit T cells against the tumor remains active. This is of significant
442 importance as it indicates that the prophylactic use of TCZ does not impede the primary anti-
443 tumor immune response facilitated by ICIs. This is a significant concern when integrating any
444 form of immunosuppression in cancer therapy. Monitoring CXCL9 levels may therefore
445 prove to be a valuable biomarker for assessing the real-time efficacy of ICI therapy. By
446 identifying and monitoring such cytokine surges, clinicians can better predict treatment
447 responses and tailor therapeutic strategies, thereby optimizing patient outcomes. This
448 approach capitalizes on the dual benefits of TCZ—managing arthritis and boosting ICI
449 efficacy—through a deeper understanding of cytokine dynamics during treatment. The
450 investigation of cytokine behavior in this context is of paramount importance and requires
451 comprehensive investigation and validation to enhance our understanding of how immune
452 modulation by TCZ impacts the success of cancer immunotherapy.

453 The observed increase in IL-6 and CXCL10 during new irAEs under TCZ prophylaxis
454 suggest that IL-6 and CXCL10 warrant close monitoring, as they may signal the emergence of
455 new irAEs. By allowing earlier detection, these biomarkers might prompt investigations and
456 targeted interventions.

457 Although the initial results of our study are encouraging, several limitations must be
458 acknowledged. First, the results are retrospective data derived from a single center with a

459 relatively small cohort, which limits the generalizability of the results to different clinical
460 settings. In addition, the study may lack diversity in patient demographics such as age, sex,
461 ethnicity, and underlying health conditions, which may affect the applicability of the findings
462 to broader populations. The potential retrospective design of the study also introduces
463 inherent biases, such as selection bias and confounding factors, which require randomized
464 controlled trials with large control arm without TCZ prophylaxis. Finally, more
465 comprehensive studies are warranted to explore how modulation of immune responses by
466 TCZ affects long-term oncologic efficacy.

467 In conclusion, this study suggests that TCZ is a viable strategy for both the treatment and
468 prevention of ICI-RA upon ICI rechallenge. This dual efficacy of TCZ could significantly
469 change the therapeutic landscape for patients undergoing ICI therapy who are at risk of, or
470 have experienced, ICI-RA. By facilitating the broader use of ICIs in cancer patients, TCZ
471 could ensure that a greater number of patients benefit from potent immunotherapy potentially
472 improving patient outcomes by maintaining uninterrupted and effective ICI treatment.

473 **Acknowledgements**

474 This work was supported by the strategic plan of the CHUV. We would like to express our
475 gratitude to all the patients who generously contributed their time and samples for this project.

476 We thank Pr Gérard Waeber for his advice. Visual abstract was created with BioRender.com.

477

478 **Author contributions**

479 MO conceived and designed the study. MO and PFP drafted the manuscript. MO, PFP and
480 DD had full access to all data in the study and take responsibility for its integrity and
481 accuracy.

482 DD, PFP and MO collected the data. PFP, DD and MO analyzed and interpreted the data. VJ
483 and RB realized the cytokine data. SL, HB, NM, KA, JD, NF, LM, AS, KS and SP
484 participated in the clinical treatments. PFP, DD and MO prepared the figures. SP. and GP
485 participated in scientific discussion. The manuscript was reviewed and approved by all
486 authors before submission.

487

488 **Conflict of interest**

489 MO received honoraria and speaker fees from Moderna, Roche and BMS.

490 **Data sharing statements**

491 The datasets supporting the results of this study are not publicly available. Requests for access
492 to the dataset will be granted upon reasonable request to the principal investigator. Study data
493 will be managed, stored, shared, and archived according to CHUV standard operating
494 procedures to ensure the continued quality, integrity, and utility of the data.

495

496

497

498 **References**

- 499 1 Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors:
500 epidemiology, management and surveillance. *Nat Rev Clin Oncol* 2019.
- 501 2 Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from
502 cancer immunotherapy. *Nat Rev Rheumatol* 2018; 14 (10): 569-579.
- 503 3 Belkhir R, Burel SL, Dunogeant L et al. Rheumatoid arthritis and polymyalgia rheumatica
504 occurring after immune checkpoint inhibitor treatment. *Ann Rheum Dis* 2017; 76 (10): 1747-
505 1750.
- 506 4 Braaten TJ, Brahmer JR, Forde PM et al. Immune checkpoint inhibitor-induced inflammatory
507 arthritis persists after immunotherapy cessation. *Ann Rheum Dis* 2020; 79 (3): 332-338.
- 508 5 Ghosh N, Tiongson MD, Stewart C et al. Checkpoint Inhibitor-Associated Arthritis: A
509 Systematic Review of Case Reports and Case Series. *J Clin Rheumatol* 2021; 27 (8): e317-
510 e322.
- 511 6 Calabrese C, Cappelli LC, Kostine M et al. Polymyalgia rheumatica-like syndrome from
512 checkpoint inhibitor therapy: case series and systematic review of the literature. *RMD Open*
513 2019; 5 (1): e000906.
- 514 7 Martin de Fremont G, Belkhir R, Henry J et al. Features of polymyalgia rheumatica-like
515 syndrome after immune checkpoint inhibitor therapy. *Ann Rheum Dis* 2022; 81 (3): e52.
- 516 8 Jeurling S, Cappelli LC. Treatment of immune checkpoint inhibitor-induced inflammatory
517 arthritis. *Curr Opin Rheumatol* 2020; 32 (3): 315-320.
- 518 9 Kim ST, Chu Y, Misoi M et al. Distinct molecular and immune hallmarks of inflammatory
519 arthritis induced by immune checkpoint inhibitors for cancer therapy. *Nat Commun* 2022; 13
520 (1): 1970.
- 521 10 Wang R, Singaraju A, Marks KE et al. Clonally expanded CD38(hi) cytotoxic CD8 T cells
522 define the T cell infiltrate in checkpoint inhibitor-associated arthritis. *Sci Immunol* 2023; 8
523 (85): eadd1591.
- 524 11 Doms J, Prior JO, Peters S et al. Tocilizumab for refractory severe immune checkpoint
525 inhibitor-associated myocarditis. *Ann Oncol* 2020; 31 (9): 1273-1275.
- 526 12 Moi L, Bouchaab H, Mederos N et al. Personalized Cytokine-Directed Therapy With
527 Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis. *J*
528 *Thorac Oncol* 2021; 16 (2): 318-326.
- 529 13 Ozdemir BC, Latifyan S, Perreau M et al. Cytokine-directed therapy with tocilizumab for
530 immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. *Ann Oncol* 2020;
531 31 (12): 1775-1778.
- 532 14 Kim ST, Tayar J, Trinh VA et al. Successful treatment of arthritis induced by checkpoint
533 inhibitors with tocilizumab: a case series. *Ann Rheum Dis* 2017; 76 (12): 2061-2064.
- 534 15 Holmstroem RB, Nielsen OH, Jacobsen S et al. COLAR: open-label clinical study of IL-6
535 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis
536 and arthritis. *J Immunother Cancer* 2022; 10 (9).
- 537 16 De La Fuente F, Belkhir R, Henry J et al. Use of a bDMARD or tsDMARD for the
538 management of inflammatory arthritis under checkpoint inhibitors: an observational study.
539 *RMD Open* 2022; 8 (2).
- 540 17 Fa'ak F, Buni M, Falohun A et al. Selective immune suppression using interleukin-6 receptor
541 inhibitors for management of immune-related adverse events. *J Immunother Cancer* 2023; 11
542 (6).
- 543 18 Nakajima EC, Lipson EJ, Brahmer JR. Challenge of Rechallenge: When to Resume
544 Immunotherapy Following an Immune-Related Adverse Event. *J Clin Oncol* 2019; 37 (30):
545 2714-2718.
- 546 19 Pollack MH, Betof A, Dearden H et al. Safety of resuming anti-PD-1 in patients with immune-
547 related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic
548 melanoma. *Ann Oncol* 2018; 29 (1): 250-255.

- 549 20 Simonaggio A, Michot JM, Voisin AL et al. Evaluation of Readministration of Immune
550 Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. *JAMA*
551 *Oncol* 2019; 5 (9): 1310-1317.
- 552 21 Dolladille C, Ederhy S, Sassier M et al. Immune Checkpoint Inhibitor Rechallenge After
553 Immune-Related Adverse Events in Patients With Cancer. *JAMA Oncol* 2020; 6 (6): 865-871.
- 554 22 Haanen J, Ernstoff M, Wang Y et al. Rechallenge patients with immune checkpoint inhibitors
555 following severe immune-related adverse events: review of the literature and suggested
556 prophylactic strategy. *J Immunother Cancer* 2020; 8 (1).
- 557 23 Badran YR, Cohen JV, Brastianos PK et al. Concurrent therapy with immune checkpoint
558 inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse
559 events. *J Immunother Cancer* 2019; 7 (1): 226.
- 560 24 Badran YR, Zou F, Durbin SM et al. Concurrent immune checkpoint inhibition and selective
561 immunosuppressive therapy in patients with immune-related enterocolitis. *J Immunother*
562 *Cancer* 2023; 11 (6).
- 563 25 Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary
564 definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995; 38 (6): 727-735.
- 565 26 van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement
566 criteria that include simplified joint counts. *Arthritis Rheum* 1998; 41 (10): 1845-1850.
- 567 27 Prevoo ML, van 't Hof MA, Kuper HH et al. Modified disease activity scores that include
568 twenty-eight-joint counts. Development and validation in a prospective longitudinal study of
569 patients with rheumatoid arthritis. *Arthritis Rheum* 1995; 38 (1): 44-48.
- 570 28 Noto A, Joo V, Mancarella A et al. CXCL12 and CXCL13 Cytokine Serum Levels Are
571 Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses. *Viruses*
572 2022; 14 (12).
- 573 29 Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of
574 glucocorticoids, recent developments and mechanistic insights. *Mol Cell Endocrinol* 2011;
575 335 (1): 2-13.
- 576 30 Libert C, Dejager L. How steroids steer T cells. *Cell Rep* 2014; 7 (4): 938-939.
- 577 31 Giles AJ, Hutchinson MND, Sonnemann HM et al. Dexamethasone-induced
578 immunosuppression: mechanisms and implications for immunotherapy. *J Immunother Cancer*
579 2018; 6 (1): 51.
- 580 32 Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor
581 microenvironment. *Semin Immunol* 2014; 26 (1): 38-47.
- 582 33 Tsukamoto H, Fujieda K, Miyashita A et al. Combined Blockade of IL6 and PD-1/PD-L1
583 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor
584 Microenvironment. *Cancer Res* 2018; 78 (17): 5011-5022.
- 585 34 Mace TA, Shakya R, Pitarresi JR et al. IL-6 and PD-L1 antibody blockade combination
586 therapy reduces tumour progression in murine models of pancreatic cancer. *Gut* 2018; 67 (2):
587 320-332.
- 588 35 Ohno Y, Toyoshima Y, Yurino H et al. Lack of interleukin-6 in the tumor microenvironment
589 augments type-1 immunity and increases the efficacy of cancer immunotherapy. *Cancer Sci*
590 2017; 108 (10): 1959-1966.
- 591 36 Huseni MA, Wang L, Klementowicz JE et al. CD8(+) T cell-intrinsic IL-6 signaling promotes
592 resistance to anti-PD-L1 immunotherapy. *Cell Rep Med* 2023; 4 (1): 100878.
- 593 37 J.S. Weber TM, O. Hamid, J. Mehnert, F.S. Hodi, S. Krishnarajapet, S. Malatyali, E.
594 Buchbinder, J. Goldberg, R. Sullivan, M. Faries, I. Mehmi. Phase II trial of ipilimumab,
595 nivolumab and tocilizumab for unresectable metastatic melanoma. *Annals of Oncology* 2021.
- 596 38 Shankar B, Zhang J, Naqash AR et al. Multisystem Immune-Related Adverse Events
597 Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung
598 Cancer. *JAMA Oncol* 2020; 6 (12): 1952-1956.
- 599 39 Hu W, Wang G, Wang Y et al. Uncoupling Therapeutic Efficacy from Immune-Related
600 Adverse Events in Immune Checkpoint Blockade. *iScience* 2020; 23 (10): 101580.
- 601 40 Hua C, Boussemart L, Mateus C et al. Association of Vitiligo With Tumor Response in
602 Patients With Metastatic Melanoma Treated With Pembrolizumab. *JAMA Dermatol* 2016; 152
603 (1): 45-51.

- 604 41 Fujii T, Colen RR, Bilen MA et al. Incidence of immune-related adverse events and its
605 association with treatment outcomes: the MD Anderson Cancer Center experience. *Invest New*
606 *Drugs* 2018; 36 (4): 638-646.
- 607 42 Yu Y, Wang S, Su N et al. Increased Circulating Levels of CRP and IL-6 and Decreased
608 Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse
609 Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. *Front Oncol*
610 2022; 12: 906824.
- 611 43 Zhang X, Lu X, Yu Y et al. Changes of IL-6 And IFN-gamma before and after the adverse
612 events related to immune checkpoint inhibitors: A retrospective study. *Medicine (Baltimore)*
613 2022; 101 (46): e31761.
- 614 44 Wei F, Sasada T. Circulating cytokine signatures as a soluble biomarker of immune checkpoint
615 inhibitor therapy in non-small-cell lung cancer. *Genes Immun* 2024; 25 (1): 89-91.
- 616 45 Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. *Curr*
617 *Rheumatol Rep* 2009; 11 (5): 365-370.
- 618 46 Agonia I, Couras J, Cunha A et al. IL-17, IL-21 and IL-22 polymorphisms in rheumatoid
619 arthritis: A systematic review and meta-analysis. *Cytokine* 2020; 125: 154813.
- 620 47 Aarts J, Roeleveld DM, Helsen MM et al. Systemic overexpression of interleukin-22 induces
621 the negative immune-regulator SOCS3 and potentially reduces experimental arthritis in mice.
622 *Rheumatology (Oxford)* 2021; 60 (4): 1974-1983.
- 623 48 Sun X, Fang C, Jin S et al. Serum IL-6 level trajectory for predicting the effectiveness and
624 safety of tocilizumab in the treatment of refractory Takayasu arteritis. *Eur J Intern Med* 2024.
- 625 49 Horisberger A, La Rosa S, Zurcher JP et al. A severe case of refractory esophageal stenosis
626 induced by nivolumab and responding to tocilizumab therapy. *J Immunother Cancer* 2018; 6
627 (1): 156.
- 628 50 Bass AR, Abdel-Wahab N, Reid PD et al. Comparative safety and effectiveness of TNF
629 inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-
630 associated arthritis. *Ann Rheum Dis* 2023; 82 (7): 920-926.
- 631 51 Michel Obeid VJ, Douglas Daoudlarian, Robin Bartolini, Hasna Bouchaab, Sofiya Latifyan,
632 Nuria Mederos, Karim Abdelhamid, Valérie Mosimann, Nabila Ferahta, Keyvan Shabafrouz,
633 Giuseppe Pantaleo, and Solange Peters. High-dimensional longitudinal immune profiling
634 uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the
635 coupling of immune-related adverse events to immune checkpoint inhibitor response. *Journal*
636 *of Clinical Oncology* 2024.
- 637 52 House IG, Savas P, Lai J et al. Macrophage-Derived CXCL9 and CXCL10 Are Required for
638 Antitumor Immune Responses Following Immune Checkpoint Blockade. *Clin Cancer Res*
639 2020; 26 (2): 487-504.

640

Figure 1




Figure 2




Table 1.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	n = 26	% within cohort
<u>Age</u>		
Mean at rh-irAE onset	70	95% CI:63-77
<u>Corhort follow-up (median, days)</u>		
Follow-up from ICI initiation	864.5	95% CI:576-1152
Follow-up from rh-irAE	564	95% CI: 384-825
<u>rh-irAEs onset</u>		
Median time of onset (days)	171	95% CI:53-326
Onset within 90 days	11	42%
<u>rh-irAEs clinical presentation</u>		
Polyarticular arthritis (>5 joints)	14	54%
PMR-like	7	27%
Oligo-arthritis (<5 joints)	5	19%
<u>Rh-irAE duration (median, days)</u>		
Rh-irAE duration	360	95% CI:271-546
<u>Biological findings</u>		
<u>Rheumatoid factor (RF)</u>		
Tested positive	0/26	0%
<u>ACPA</u>		
Tested positive	0/26	0%
<u>Gender</u>		
Male	15	58%
Female	11	42%
<u>Tumor type</u>		
Melanoma	11	42%
Lung	11	42%
Head and neck	2	8%
Colorectal	1	4%
Renal cell carcinoma	1	4%
<u>Initial ICI therapy</u>		
Nivolumab/ipilimumab	8	31%
Nivolumab/relatlimab	1	4%
Anti PD-1 monotherapy	16	62%
Anti PD-L1 monotherapy	1	4%
<u>Pre-existing rheumatic diseases</u>		
Polymyalgia rheumatica	3	12%
Seronegative polyarthritis	1	4%
Axial spondyloarthritis	1	4%
<u>Concomitant irAE</u>		
Colitis	3	12%
Cutaneous	2	8%
Hepatitis	2	8%
Endocrine	4	15%
Pneumonitis	1	4%
Myositis	2	8%

Table 2

	n = 26	% within cohort			
<u>Immunosuppressive treatment</u>					
1L corticosteroids (CS) alone	6				23%
1L tocilizumab (TCZ) + CS	18				69%
1L TCZ Alone	2				8%
<u>Response to treatment</u>					
	with TCZ n = 20 (78%)	%	with CS n=6 (22%)	%	
ACR50 at W10-12	20 out of 20	100%	6 out of 6		100%
ACR70 at W10-12	20 out of 20	100%	6 out of 6		100%
ACR70 at W24	16 out of 16	100%	4 out of 4		100%
Steroid-free 24W	13 out of 16	81%	1 out of 4		25%
<u>Treatment characteristics</u>					
Mean CS dose (mg)	23		37.5		
Time for <10mg CS (mean days)	N/A		40.25		
Time for <10mg CS after TCZ (mean days)	30.7		N/A		
TCZ duration (median days)	235		N/A		


Table 3

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	Without TCZ Prophylaxis		With TCZ Prophylaxis	
	n = 5	%	n = 11	%
Patients with >1 rechallenge	2	40%	1	9%
Median Interval between end of initial ICI and rechallenge	70	95% CI:56-84	22.5	95% CI:20-295
Rechallenge for PD	2	40%	4	36%
<u>Tumor type</u>				
Lung	2	67%	5	50%
Melanoma	1	33%	4	40%
Colorectal	0	0%	1	10%
<u>Rechallenge as compared to initial ICI therapy</u>				
Similar ICI	3	60%	10	91%
Nivolumab to ipilimumab/nivolumab	0	0%	1	9%
Nivolumab to pembrolizumab/chemotherapy	1	20%	0	0%
Nivolumab to nivolumab/relatlimab	1	20%	0	0%
<u>rh-irAE evolution</u>				
Requiring steroids >0.1 mg/kg for Arthritis	1	20%	0	0%
Relapse rh-irAE ≥ G2	2	40%	2	18%
<u>Other irAEs</u>				
Colitis ≥ G2	1	20%	5	45%
CRS G1	0	0%	1	9%
Pneumonitis	1	20%	0	0%
<u>ICI rechallenge interruption</u>				
Due to rh-irAEs flares	0	0%	0	0%
Due to others irAEs types	2	40%	3	27%
Due to disease control	1	20%	1	9%
Due to neutropenia	0	0%	1	9%
Due to end of adjuvant treatment	0	0%	1	9%
Due to PD	2	40%	0	0%
Patient decision	0	0%	1	9%
<u>ICI treatment duration</u>				
Mean duration (days)	113	95% CI:16-210	206	95% CI:78-333
ICI > 90 days	2	40%	6	55%
Ongoing ICI at least follow-up	0	0%	4	36%
Median follow up after rechallenge (days)	566	95% CI:129-757	498	95% CI:341-1040

Supplementary Table 1

	Patient without ICI rechallenge (n=13)		Patient with ICI rechallenge (n=13)	
<u>Oncological outcome 6 months after initial rh-irAE</u>				
Complete Response (CR)	1	8%	3	23%
Partial Response (PR)	3	23%	3	23%
Adjuvant no PD	3	23%	2	15%
Oligo-PD	3	23%	2	15%
PD	1	8%	3	23%
Death	1	8%	0	0%
Unknown	1	8%	0	0%
Disease Control Rate (DCR)	7	78%	8	73%
<u>Oncological outcome 12 months after initial rh-irAE</u>				
Complete Response (CR)	1	8%	4	31%
Partial Response (PR)	2	15%	2	15%
Adjuvant no PD	3	23%	2	15%
Oligo-PD	2	15%	2	15%
PD	0	0%	2	15%
Death	2	15%	1	8%
Unknown	3	23%	0	0%
Disease Control Rate (DCR)	5	71%	8	73%
<u>Oncological outcome 6 months after ICI rechallenge</u>			n=11	
Complete Response (CR)			4	36%
Partial Response (PR)			3	27%
Stable Disease (SD)			2	18%
Progressive Disease (PD)			1	9%
Death			1	9%
Disease Control Rate (DCR)			9	82%
<u>Oncological outcome 12 months after ICI rechallenge</u>			n=10	
Complete Response (CR)			6	60%
Partial Response (PR)			1	10%
Stable Disease (SD)			0	0%
Progressive Disease (PD)			2	20%
Death			1	10%
Disease Control Rate (DCR)			7	70%



TAPIR Retrospective Study Design

(Tocilizumab For Arthritis Prevention with Rh-irAEs)

